These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11916089)

  • 1. Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation.
    Borja J; Olivella P
    Thromb Haemost; 2002 Mar; 87(3):538. PubMed ID: 11916089
    [No Abstract]   [Full Text] [Related]  

  • 2. Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation.
    Cohen M; Antman EM
    Thromb Haemost; 2002 Nov; 88(5):884-6; 886-7. PubMed ID: 12428118
    [No Abstract]   [Full Text] [Related]  

  • 3. [Enoxaparin failed to show superiority to unfractionated heparin in patients with non ST-elevation acute coronary syndrome in a phase of A to Z trial].
    Gratsianskiĭ NA
    Kardiologiia; 2003; 43(6):70-1. PubMed ID: 12974259
    [No Abstract]   [Full Text] [Related]  

  • 4. Enoxaparin in non-ST segment elevation acute coronary syndromes: duration of therapy is essential to benefit.
    Steg PG; Juliard JM
    Eur Heart J; 2004 Oct; 25(19):1667-9. PubMed ID: 15451141
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of enoxaparin over unfractionated heparin for the treatment of acute coronary syndromes.
    Cohen M; Antman EM
    Pharmacotherapy; 2002 Apr; 22(4):542-6; author reply 546-50. PubMed ID: 11939692
    [No Abstract]   [Full Text] [Related]  

  • 7. Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin.
    Gurfinkel E; Duronto E; Colorio C; Bozovich G; Cohen M; Mautner B
    J Thromb Thrombolysis; 1999 Oct; 8(3):227-32. PubMed ID: 10500313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin in clinical practice and clinical trials of non-ST-elevation Acute Coronary Syndrome (NSTE-ACS).
    Das P; Moliterno DJ
    J Thromb Thrombolysis; 2005 Apr; 19(2):105-13. PubMed ID: 16052301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit of enoxaparin in patients with high-risk acute coronary syndromes without ST elevations in clinical practice.
    Zeymer U; Gitt A; Jünger C; Koeth O; Zahn R; Wienbergen H; Gottwik M; Senges J;
    Am J Cardiol; 2006 Jul; 98(1):19-22. PubMed ID: 16784913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.
    Ferguson JJ; Califf RM; Antman EM; Cohen M; Grines CL; Goodman S; Kereiakes DJ; Langer A; Mahaffey KW; Nessel CC; Armstrong PW; Avezum A; Aylward P; Becker RC; Biasucci L; Borzak S; Col J; Frey MJ; Fry E; Gulba DC; Guneri S; Gurfinkel E; Harrington R; Hochman JS; Kleiman NS; Leon MB; Lopez-Sendon JL; Pepine CJ; Ruzyllo W; Steinhubl SR; Teirstein PS; Toro-Figueroa L; White H;
    JAMA; 2004 Jul; 292(1):45-54. PubMed ID: 15238590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-molecular weight heparin enoxaparin in the treatment of acute coronary syndromes without ST segment elevation.
    Mitrovska S; Jovanova S
    Bratisl Lek Listy; 2009; 110(1):45-8. PubMed ID: 19408831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome.
    Jolly S; Tan M; Mendelsohn A; Fitchett D; Armstrong PW; Langer A; Goodman SG
    Am J Cardiol; 2007 Jan; 99(2):186-8. PubMed ID: 17223416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Jin Z; Wang L; Ramasamy S; Poddar KL; Minami Y; Park JY; Choi CU; Oh DJ; Jeong MH;
    J Cardiol; 2012 Jan; 59(1):22-9. PubMed ID: 22079855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
    JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial.
    Fitchett DH; Langer A; Armstrong PW; Tan M; Mendelsohn A; Goodman SG;
    Am Heart J; 2006 Feb; 151(2):373-9. PubMed ID: 16442903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
    Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
    Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.